<DOC>
	<DOCNO>NCT00476242</DOCNO>
	<brief_summary>Prospective participant undergo screen process clinic determine eligibility . After screen , eligible patient complete 8-day inpatient detoxification , follow 12-week outpatient phase . Patients randomly assign one two condition ( 1 ) Naltrexone + Placebo ; ( 2 ) Naltrexone + Memantine 20 mg bid . Long-acting , injectable form naltrexone ( Vivitrol ) administer per month ( total three injection ) memantine placebo take daily . In addition , patient receive twice weekly psychosocial intervention include motivational interview cognitive-behavioral relapse prevention . The outpatient treatment also consist 3 weekly visit clinic patient receive counsel help maintain abstinence improve compliance study medication .</brief_summary>
	<brief_title>Memantine Supplement Naltrexone Treating Heroin Dependence</brief_title>
	<detailed_description>In propose trial heroin-dependent patient undergo detoxification randomly assign one two condition ( 1 ) Naltrexone + Placebo ; ( 2 ) Naltrexone + Memantine 20 mg bid . Long-acting , injectable form naltrexone ( Vivitrol ) administer per month ( total three injection ) memantine placebo take daily . In addition , patient receive twice weekly psychosocial intervention include motivational interview cognitive-behavioral relapse prevention . The goal psychosocial intervention improve compliance medication maintain abstinence . A double-blind trial last twelve week assessment baseline appointment three time per week . After completion double-blind study ( experimental phase ) , participant continue open label treatment Vivitrol therapy additional three month ( study extension phase ) . Repeated assessment also complete one , two , three month follow end double-blind treatment . For experimental phase study , primary aim test efficacy memantine reduce early attrition improve outcome opioid-dependent individual maintain naltrexone primary outcome measure retention treatment end study heroin abstinence .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Adult , aged 1860 . 2 . Meets Diagnostic Statistical Manual IV ( DSMIV ) criteria current opiate dependence disorder least six month duration , support positive urine opiate positive naloxone challenge test diagnosis unclear . 3 . Able give inform consent . 1 . Pregnancy , lactation , failure sexually active woman use adequate contraceptive method . 2 . Active medical illness might make participation hazardous , untreated hypertension , acute hepatitis serum glutamic oxaloacetic transaminase serum glutamicpyruvic transaminase level &gt; 2 time normal , unstable diabetes , chronic organic mental disorder ( e.g. , AIDS dementia ) . 3 . Active psychiatric disorder might interfere participation make participation hazardous , include DSMIV schizophrenia , bipolar disorder mania psychosis , depressive disorder suicide risk 1 suicide attempt within past year . 4 . History allergic reaction buprenorphine , naloxone , memantine , naltrexone , clonidine , clonazepam . 5 . Currently prescribe regularly take opiate chronic pain medical illness . 6 . Current participation another intensive psychotherapy substance abuse treatment program currently prescribe psychotropic medication . 7 . Current participation methadone maintenance treatment program and/or regular use illicit methadone ( &gt; 30 mg per week ) . 8 . History accidental drug overdose last three year significant history overdose follow detoxification define episode opioidinduced unconsciousness incapacitation , whether medical treatment seek receive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>heroin abuse</keyword>
	<keyword>opiate abuse</keyword>
	<keyword>opioid dependence</keyword>
	<keyword>naltrexone</keyword>
	<keyword>memantine</keyword>
</DOC>